Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$485.99 USD
+4.10 (0.85%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $486.28 +0.29 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum D VGM
Brokerage Reports
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 121 - 140 ( 329 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: November 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Trikafta FDA Approval and NHS England Agreement Present the Quarter With a Hammer
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Spotlight on NACFC 2019: Hot Topics and Abstracts of Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Beyond CF, Pipeline Advancement Continues in AATD and APOL1 Kidney Disease; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Alpha-1 KOL Offers Perspective on Current AATD Approaches and VX-814, Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
KOL Reception and Dinner on Alpha-1 Antitrypsin Deficiency (AATD)
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Strategic Collaboration Adds Targeted Protein Degradation Expertise to Developmental Arsenal; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Beyond Cystic Fibrosis: Thoughts Around AATD Therapy Development; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A